JP2005533799A - 新規なるキヌクリジンカルバミン酸誘導体およびそれを含む医薬組成物 - Google Patents

新規なるキヌクリジンカルバミン酸誘導体およびそれを含む医薬組成物 Download PDF

Info

Publication number
JP2005533799A
JP2005533799A JP2004514785A JP2004514785A JP2005533799A JP 2005533799 A JP2005533799 A JP 2005533799A JP 2004514785 A JP2004514785 A JP 2004514785A JP 2004514785 A JP2004514785 A JP 2004514785A JP 2005533799 A JP2005533799 A JP 2005533799A
Authority
JP
Japan
Prior art keywords
ylmethyl
azoniabicyclo
octane
optionally substituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004514785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533799A5 (cg-RX-API-DMAC10.html
Inventor
マリア・プラト・キノネス
マリア・アントニア・ブイル・アルベロ
マリア・ドロルス・フェルナンデス・フォルネル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall AG
Original Assignee
Almirall Prodesfarma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma AG filed Critical Almirall Prodesfarma AG
Publication of JP2005533799A publication Critical patent/JP2005533799A/ja
Publication of JP2005533799A5 publication Critical patent/JP2005533799A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004514785A 2002-06-21 2003-06-18 新規なるキヌクリジンカルバミン酸誘導体およびそれを含む医薬組成物 Pending JP2005533799A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200201439A ES2203327B1 (es) 2002-06-21 2002-06-21 Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
PCT/EP2003/006472 WO2004000840A2 (en) 2002-06-21 2003-06-18 Quinuclidine derivatives and pharmaceutical compositions containing the same

Publications (2)

Publication Number Publication Date
JP2005533799A true JP2005533799A (ja) 2005-11-10
JP2005533799A5 JP2005533799A5 (cg-RX-API-DMAC10.html) 2006-07-06

Family

ID=29797397

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004514785A Pending JP2005533799A (ja) 2002-06-21 2003-06-18 新規なるキヌクリジンカルバミン酸誘導体およびそれを含む医薬組成物

Country Status (21)

Country Link
US (3) US7435742B2 (cg-RX-API-DMAC10.html)
EP (1) EP1515968A2 (cg-RX-API-DMAC10.html)
JP (1) JP2005533799A (cg-RX-API-DMAC10.html)
CN (1) CN100363363C (cg-RX-API-DMAC10.html)
AR (1) AR040275A1 (cg-RX-API-DMAC10.html)
AU (1) AU2003279384A1 (cg-RX-API-DMAC10.html)
BR (1) BR0312169A (cg-RX-API-DMAC10.html)
CA (1) CA2490082A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP045484A (cg-RX-API-DMAC10.html)
ES (1) ES2203327B1 (cg-RX-API-DMAC10.html)
IL (1) IL165775A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA04012272A (cg-RX-API-DMAC10.html)
NO (1) NO20050217L (cg-RX-API-DMAC10.html)
NZ (1) NZ537252A (cg-RX-API-DMAC10.html)
PE (1) PE20040579A1 (cg-RX-API-DMAC10.html)
RU (1) RU2321588C2 (cg-RX-API-DMAC10.html)
TW (1) TW200401776A (cg-RX-API-DMAC10.html)
UA (1) UA85541C2 (cg-RX-API-DMAC10.html)
UY (1) UY27850A1 (cg-RX-API-DMAC10.html)
WO (1) WO2004000840A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200410211B (cg-RX-API-DMAC10.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544659A (ja) * 2006-07-26 2009-12-17 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｍ３アンタゴニストとしてのキヌクリジン誘導体
JP2010519299A (ja) * 2007-02-23 2010-06-03 セラヴァンス， インコーポレーテッド ムスカリン受容体アンタゴニストとして有用な第四級アンモニウムジフェニルメチル化合物
JP2011504890A (ja) * 2007-11-28 2011-02-17 ラボラトリオス・サルバト・ソシエダッド・アノニマ （ｒ）−３−フルオロフェニル−３，４，５−トリフルオロベンジルカルバミン酸１−アザビシクロ［２．２．２］オクト−３−イルエステルの安定な結晶性塩
JP5293192B2 (ja) * 2007-02-09 2013-09-18 アステラス製薬株式会社 アザ架橋環化合物
JP2014517808A (ja) * 2011-03-18 2014-07-24 ジェンザイム・コーポレーション グルコシルセラミド合成酵素阻害剤
JPWO2022145408A1 (cg-RX-API-DMAC10.html) * 2020-12-28 2022-07-07

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1345937B1 (en) * 2000-12-22 2005-09-28 Almirall Prodesfarma AG Quinuclidine carbamate derivatives and their use as m3 antagonists
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
EP1781298B1 (de) * 2004-04-22 2012-01-04 Boehringer Ingelheim International GmbH Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen
WO2006005057A2 (en) * 2004-06-30 2006-01-12 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
ES2246170B1 (es) * 2004-07-29 2007-04-01 Almirall Prodesfarma, S.A. Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
EP1917253B1 (de) 2005-08-15 2015-01-07 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von betamimetika
DE102006028286A1 (de) * 2006-06-20 2007-12-27 Wirsich, Konrad, Dipl.-Ing. (FH) Drehmoment- und rutschfest verbundene aus zwei Teilen bestehende Schaltzahnräder
EP2080507A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Pharmaceutical formulations comprising an anticholinergic drug
ES2655083T3 (es) * 2010-01-28 2018-02-16 Theron Pharmaceuticals, Inc. Derivados de 7-azoniabiciclo [2.2.1]heptano, métodos de producción, y usos farmacéuticos de estos
EP2631674A1 (de) * 2012-02-23 2013-08-28 ELMOS Semiconductor AG Verfahren und Sensorsystem zur Vermessung der Eigenschaften einer Übertragungsstrecke eines Messsystems zwischen Sender und Empfänger
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
RU2641285C2 (ru) * 2013-07-13 2018-01-17 Бэйцзин Фсвэлкам Текнолоджи Девелопмент Ко., Лтд Соединения хинина, способ их получения и их медицинское применение
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
PT3920912T (pt) 2019-02-04 2025-09-09 Genzyme Corp Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
IL295255A (en) 2020-02-03 2022-10-01 Genzyme Corp Methods for treating neurological symptoms associated with lysosomal storage diseases
CN115605202B (zh) 2020-03-26 2025-10-28 盐野义制药株式会社 具有血清素受体结合活性的芳香族杂环衍生物
IL300090A (en) 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04500521A (ja) * 1988-11-01 1992-01-30 ファイザー・インコーポレーテッド ムスカリンレセプター拮抗薬
WO1995006635A1 (en) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
WO1995021820A1 (en) * 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
WO1998005641A1 (en) * 1996-08-01 1998-02-12 Banyu Pharmaceutical Co., Ltd. Fluorinated 1,4-disubstituted piperidine derivatives
WO2001004118A2 (en) * 1999-07-14 2001-01-18 Almirall Prodesfarma S.A. Quinuclidine derivatives and their use as muscarinic m3 receptor ligands
WO2002000652A1 (es) * 2000-06-27 2002-01-03 Laboratorios S.A.L.V.A.T., S.A. Carbamatos derivados de arilalquilaminas
JP2004530641A (ja) * 2000-12-22 2004-10-07 アルミラル・プロデスフアルマ・アクチエンゲゼルシヤフト キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
JP2005516954A (ja) * 2001-12-20 2005-06-09 ラボラトリオス・エセ・ア・エレ・ベ・ア・テ・ソシエダッド・アノニマ １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2762796A (en) * 1956-09-11 Iminodibenzyl derivative
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
GB1246606A (en) 1969-04-28 1971-09-15 Starogardzkie Zakl Farma Dibenzo-azepine derivatives
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
GB9201751D0 (en) 1992-01-28 1992-03-11 Smithkline Beecham Plc Compounds
GB9202443D0 (en) 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
ATE205490T1 (de) 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
AUPN862996A0 (en) 1996-03-13 1996-04-04 Fujisawa Pharmaceutical Co., Ltd. A novel substituted-acetamide compound
SI1353919T1 (sl) 2000-12-28 2006-12-31 Almirall Prodesfarma Ag Novi derivati kinuklidina in medicinske zmesi, kijih vsebujejo.
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04500521A (ja) * 1988-11-01 1992-01-30 ファイザー・インコーポレーテッド ムスカリンレセプター拮抗薬
WO1995006635A1 (en) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
WO1995021820A1 (en) * 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
WO1998005641A1 (en) * 1996-08-01 1998-02-12 Banyu Pharmaceutical Co., Ltd. Fluorinated 1,4-disubstituted piperidine derivatives
WO2001004118A2 (en) * 1999-07-14 2001-01-18 Almirall Prodesfarma S.A. Quinuclidine derivatives and their use as muscarinic m3 receptor ligands
WO2002000652A1 (es) * 2000-06-27 2002-01-03 Laboratorios S.A.L.V.A.T., S.A. Carbamatos derivados de arilalquilaminas
JP2004530641A (ja) * 2000-12-22 2004-10-07 アルミラル・プロデスフアルマ・アクチエンゲゼルシヤフト キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
JP2005516954A (ja) * 2001-12-20 2005-06-09 ラボラトリオス・エセ・ア・エレ・ベ・ア・テ・ソシエダッド・アノニマ １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544659A (ja) * 2006-07-26 2009-12-17 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｍ３アンタゴニストとしてのキヌクリジン誘導体
JP5293192B2 (ja) * 2007-02-09 2013-09-18 アステラス製薬株式会社 アザ架橋環化合物
JP2010519299A (ja) * 2007-02-23 2010-06-03 セラヴァンス， インコーポレーテッド ムスカリン受容体アンタゴニストとして有用な第四級アンモニウムジフェニルメチル化合物
JP2011504890A (ja) * 2007-11-28 2011-02-17 ラボラトリオス・サルバト・ソシエダッド・アノニマ （ｒ）−３−フルオロフェニル−３，４，５−トリフルオロベンジルカルバミン酸１−アザビシクロ［２．２．２］オクト−３−イルエステルの安定な結晶性塩
JP2014517808A (ja) * 2011-03-18 2014-07-24 ジェンザイム・コーポレーション グルコシルセラミド合成酵素阻害剤
JP2017141255A (ja) * 2011-03-18 2017-08-17 ジェンザイム・コーポレーション グルコシルセラミド合成酵素阻害剤
JPWO2022145408A1 (cg-RX-API-DMAC10.html) * 2020-12-28 2022-07-07
WO2022145408A1 (ja) * 2020-12-28 2022-07-07 塩野義製薬株式会社 セロトニン受容体結合活性を有する環状アミン誘導体
JP7741820B2 (ja) 2020-12-28 2025-09-18 塩野義製薬株式会社 セロトニン受容体結合活性を有する環状アミン誘導体

Also Published As

Publication number Publication date
US20060094751A1 (en) 2006-05-04
US20090005412A1 (en) 2009-01-01
ZA200410211B (en) 2005-09-06
WO2004000840A2 (en) 2003-12-31
RU2321588C2 (ru) 2008-04-10
IL165775A0 (en) 2006-01-15
CN100363363C (zh) 2008-01-23
US20090054480A1 (en) 2009-02-26
UY27850A1 (es) 2003-11-28
AU2003279384A1 (en) 2004-01-06
MXPA04012272A (es) 2005-04-08
EP1515968A2 (en) 2005-03-23
ES2203327B1 (es) 2005-06-16
ECSP045484A (es) 2005-01-28
US7435742B2 (en) 2008-10-14
ES2203327A1 (es) 2004-04-01
RU2005101409A (ru) 2005-11-20
NO20050217L (no) 2005-03-18
CA2490082A1 (en) 2003-12-31
TW200401776A (en) 2004-02-01
AR040275A1 (es) 2005-03-23
UA85541C2 (ru) 2009-02-10
PE20040579A1 (es) 2004-09-08
NZ537252A (en) 2006-07-28
CN1675206A (zh) 2005-09-28
WO2004000840A3 (en) 2004-02-19
BR0312169A (pt) 2005-03-29

Similar Documents

Publication Publication Date Title
US20090005412A1 (en) Novel quinuclidine derivatives and medicinal compositions containing the same
JP4445704B2 (ja) キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
US7879874B2 (en) Quinuclidine derivatives and medicinal compositions containing the same
US7718670B2 (en) Quinuclidine amide derivatives
AU2002228015A1 (en) Quinuclidine carbamate derivatives and their use as M3 antagonists
WO2010015324A1 (en) Quinuclidine carbonate derivatives and medicinal composition thereof
KR20050024366A (ko) 퀴누클리딘 유도체 및 이를 함유하는 약학 조성물
KR20050024450A (ko) 신규한 퀴누클리딘 아미드 유도체
HK1055120B (en) Quinuclidine carbamate derivatives and their use as m3 antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060516

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20071019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100713